Insights
Search Results
Newsletters
6.03.26
The Life Sciences Report – June 2026
This latest edition features articles on accelerating new therapies under the new FDA administration, cash-pay healthcare companies possibly facing kickback and fee-splitting risk under federal and state laws, building in-house legal teams for biotech, digital health, and medical devices companies, and life sciences venture financings for firm clients across 1H2025 and 2H2025.
Client Highlights
5.06.26
Wilson Sonsini Advises BioOrbit on $13.2 Million Seed Round
On April 30, 2026, BioOrbit, a space manufacturing company developing hardware for the large-scale crystallization of protein drugs, announced the completion of a $13.2 million (£9.8 million) seed round co-led by LocalGlobe and BREEGA, with support from Seedcamp, Auxxo Female Catalyst Fund, Type One Ventures, 7percent Ventures and other investors. Wilson Sonsini Goodrich & Rosati advised BioOrbit on the transaction.
Client Highlights
4.27.26
Wilson Sonsini Advises Nervonik on $52.5 Million Series B Financing
On April 27, 2026, Nervonik, a clinical-stage medical device company developing next-generation peripheral nerve stimulation (PNS) technologies, announced the closing of an oversubscribed $52.5 million Series B financing. The round was led by Amzak Health, with participation from Elevage Medical Technologies, U.S. Venture Partners (USVP), Lumira Ventures, Foothill Ventures, and Shangbay Capital. The proceeds from the financing will support the continued development and commercialization of Nervonik's PNS system, including further development of its proprietary sensing capabilities. Wilson Sonsini Goodrich & Rosati advised Nervonik on the transaction.
Client Highlights
4.20.26
Wilson Sonsini Advises Novo Holdings on Route 92 Medical’s $50 Million Growth Financing
On April 7, 2026, Route 92 Medical, a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, announced a $50 million growth financing led by Novo Holdings. New investor Sectoral Asset Management and existing investors U.S. Venture Partners, Norwest Venture Partners, InnovaHealth Partners, and The Vertical Group joined in the financing round. Wilson Sonsini Goodrich & Rosati advised Novo Holdings on the transaction.
Client Highlights
4.02.26
Wilson Sonsini Advises View Point Medical on Acquisition by Merit Medical
On April 1, 2026, Merit Medical Systems, Inc., a global leader of healthcare technology, announced it has acquired View Point Medical, Inc. The aggregate transaction consideration, including the assumption of View Point liabilities, is approximately $140 million. Wilson Sonsini Goodrich & Rosati advised View Point on the transaction.
Alerts
1.22.26
2026 Antitrust Year in Preview
Last year was a landmark in the development of antitrust law. Enforcers, legislators, and private parties grappled with the fundamental shift represented by artificial intelligence (AI) technologies, the resolution of important digital technology antitrust cases, and significant divergence in policy across a presidential administration transition. The changes will not stop in 2026. In this preview, we focus on several economic sectors that were most impacted by developments in antitrust law in 2025 to identify the trends that will drive governmental and private activity in antitrust in 2026.
Newsletters
1.07.26
The Life Sciences Report – January 2026
This latest edition features articles on reasons for optimism around 2026 life sciences fundraising, key IP priorities for biotech and biopharma following Series B financing, the default rules of joint patent rights worldwide, the evolving role of innovation theories of harm in the antitrust analysis of life science mergers, life sciences venture financings for firm clients across 2H2024 and 1H2025, and how Wilson Sonsini helped ensure Light Horse Therapeutics’ impressive debut. The report also includes details on the most recent Biotech Summit and Phoenix Conference, the LaunchBio East Coast NextGen VC Forum, the latest episodes of the NextGen VC Podcast focused on life sciences investing, and the Patents and Innovations Library for in-house IP counsel, as well as select life sciences client highlights and upcoming events.
Client Highlights
12.15.25
Wilson Sonsini Advises SpectraWAVE on Acquisition by Philips
On December 15, 2025, Royal Philips announced it has entered into an agreement to acquire Massachusetts-based SpectraWAVE, an innovator in enhanced vascular imaging of coronary arteries, angiography-based physiology assessments, and the use of AI in medical imaging. Wilson Sonsini Goodrich & Rosati is advising SpectraWAVE on the transaction.
Newsletters
12.04.25
2025 Silicon Valley 150 Corporate Governance Report
Wilson Sonsini’s 2025 Silicon Valley 150 Corporate Governance Report reviews the corporate governance practices and disclosures of Silicon Valley’s largest public companies. The report includes information regarding board matters, officer matters, defensive measures, proxy statement disclosures, environmental, social, and governance (ESG) and sustainability reporting, stockholder proposals, activism, and executive compensation of the SV150 companies.
Client Highlights
11.26.25
Wilson Sonsini Advises Revival Healthcare Capital on $150 Million Series G Financing of Distalmotion SA
On November 17, 2025, Revival Healthcare Capital and Distalmotion SA, a global medical device company based in Lausanne, Switzerland, and empowering access to the benefits of robotic surgery in outpatient sites of care, announced the successful closing of a $150 million Series G financing round of Distalmotion SA led by Revival Healthcare Capital, with participation from existing investors. Wilson Sonsini Goodrich & Rosati advised Revival Healthcare Capital on the fundraise.
Client Highlights
10.28.25
Wilson Sonsini Advises WuXi AppTec on Sale of China-Based Clinical Research Services Business to Hillhouse
On October 24, 2025, WuXi AppTec Co., Ltd. (WuXi AppTec), a leading global provider of R&D and manufacturing-enabling services in the pharmaceutical, biotechnology, and medical device industries, announced that its wholly owned subsidiary has entered into a sale and purchase agreement to sell its two subsidiaries, WuXi Clinical Development Services (Shanghai) Co., Ltd. (WuXi Clinical) and WuXi MedKey Med-Tech Development (Shanghai) Co., Ltd. (WuXi MedKey), to Hillhouse Investment Management (Hillhouse), one of the world’s leading global private asset managers focusing on sectors such as healthcare, manufacturing, green energy, hard technology, and consumer technology. WuXi Clinical and WuXi MedKey are the operating entities of WuXi AppTec engaged in China-based clinical research services.
Wilson Sonsini Goodrich & Rosati advised WuXi AppTec on the transaction. The Wilson Sonsini team includes:
Wilson Sonsini Goodrich & Rosati advised WuXi AppTec on the transaction. The Wilson Sonsini team includes: